Page 1502 - Williams Hematology ( PDFDrive )

1476 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1477

216. Sattler M, Verma S, Shrinkhande G, et al: The BCR/ABL tyrosine kinase induces pro- 246. Thompson RB, Stainsby D: The clinical and haematological features of chronic granu-
duction of reactive species in hematopoietic cells. J Biol Chem 275:24273, 2000. locytic leukaemia in the chronic phase, in Chronic Granulocytic Leukaemia, edited by
217. Sattler M, Salgia R, Okuda K, et al: The proto-oncogene product p120CBL and the Shaw MT, p 137. Praeger, East Sussex, UK, 1982.
adaptor proteins CRKL and c-CR link c-ABL, p190BCR/ABL and p210BCR/ABL to 247. Cortes JE, Talpaz M, Kantarkian H: Chronic myelogenous leukemia: A review. Am J
the phosphatidylinositol-3; kinase pathway. Oncogene 12:832, 1996. Med 100:555, 1996.
218. Salgia R, Sattler M, Pisick E, et al: P210BCR/ABL induces formation of complexes 248. Goldman JM: Chronic myeloid leukemia. Curr Opin Hematol 4:277, 1997.
containing focal adhesion proteins and the protooncogene product p120c-CBL. Exp 249. Lichtman MA, Rowe JM: Hyperleukocytic leukemias: Rheological, clinical and thera-
Hematol 24:310, 1996. peutic considerations. Blood 60:279, 1982.
219. De Jong R, van Wijk A, Haataja L, et al: BCR/ABL-induced leukemogenesis causes 250. Rowe JM, Lichtman MA: Hyperleukocytosis and leukostasis: Common features of
phosphorylation of Hef2 and its association with Crkl. J Biol Chem 272:32649, 1997. childhood chronic myelogenous leukemia. Blood 63:1230, 1984.
220. Bollag G, Clapp DW, Shih S, et al: Loss of NF1 results in activation of the Ras signaling 251. Lichtman MA, Heal J, Rowe JM: Hyperleukocytic leukaemia. Baillieres Clin Haematol
pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144, 1996. 1:725, 1987.
221. Carpino N, Wisniewski D, Strife A, et al: P62dok: A constitutively tyrosine-phospho- 252. Ungaro PC, Gonzalez JJ, Werk EE, MacKay JC: Chronic myelogenous leukemia pre-
rylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. senting clinically as diabetes insipidus. N C Med J 45:640, 1984.
Cell 88:197, 1997. 253. Juan D, Hsu SD, Hunter J: Case report of vasopressin-responsive diabetes insipidus
222. Yamanashi Y, Baltimore D: Identification of the Abl- and ras GAP-associated 62 kDa associated with chronic myelogenous leukemia. Cancer 56:1468, 1985.
protein as a docking protein, Dok. Cell 88:205, 1997. 254. Brydon J, Lucky PA, Duffy T: Acne urticaria associated with chronic myelogenous
223. Reuther JY, Reuther GW, Cortez D, et al: A requirement for NFkappaB activation in leukemia. Cancer 56:2083, 1985.
BCR/ABL-mediated transformation. Genes Dev 1:12:968, 1998. 255. Cohen PR, Talpaz M, Kurzrock R: Malignancy-associated Sweet’s syndrome: A review
224. LaMontagne KR, Flint AJ, Franza BR, et al: Protein tyrosine phosphatase 1B antag- of the world’s literature. J Clin Oncol 6:1887, 1988.
onizes signalling by oncoprotein tyrosine kinase p210 bcr/abl in vivo. Mol Cell Biol 256. López JLB, Fonseca E, Mauso F: Sweet’s syndrome during the chronic phase of chronic
18:2965, 1998. myeloid leukemia. Acta Haematol 84:207, 1990.
225. Chai SK, Nichols GL, Rothman P: Constitutive activation of JAKs and STATs in 257. Nestok BR, Goldstein JD, Lipkovic P: Splenic rupture as a cause of sudden death in
BCR-abl-expressing cell lines and peripheral blood cells derived from leukemic undiagnosed chronic myelogenous leukemia. Am J Forensic Med Pathol 9:241, 1988.
patients. J Immunol 159:4720, 1997. 258. Giagounidis AAN, Burk M, Meckenstock G, et al: Pathological rupture of the spleen
226. Shuai K, Halpern J, ten Hoeve J, et al: Constitutive activation of STAT5 by the BCR- in hematologic malignancies. Ann Hematol 73:297, 1996.
ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247, 1996. 259. Hild DH, Myers TJ: Hyperviscosity in chronic granulocytic leukemia. Cancer 46:1418,
227. Wilson-Rawls J, Xie S, Liu J, et al: P210 Bcr-Abl interacts with the interleukin 3 recep- 1980.
tor beta (c) subunit and constitutively induces its tyrosine phosphorylation. Cancer 260. D’Hondt L, Guillaume TH, Hemblit Y, Symann M: Digital necrosis associated with
Res 56:3426, 1996. chronic myeloid leukemia. Acta Clin Belg 52:49, 1997.
228. Chuang TH, Xu X, Kaartinen V, et al: Abl and Bcr are multifunctional regulators of the 261. Arbaje YM, Betran G: Chronic myelogenous leukemia complicated by autoimmune
Rho GTP-binding protein family. Proc Natl Acad Sci U S A 92:10282, 1995. hemolytic anemia. Am J Med 88:197, 1990.
229. Afar DE, Witte O: Characterization of breakpoint cluster region kinase and SH2- 262. Steegmann JL, Pinilla I, Requena MJ, et al: The direct antiglobulin test is frequently
binding activities. Methods Enzymol 256:125, 1995. positive in chronic myeloid leukemia patients treated with interferon-alpha. Transfu-
230. Gishizky ML, Cortez D, Pendergast AM: Mutant forms of growth factor-binding sion 37:446, 1997.
protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci U S A 92: 263. Hoppin EC, Lewis JP: Polycythemia rubra vera progressing to Ph1-positive chronic
10889, 1995. myelogenous leukemia. Ann Intern Med 83:820, 1975.
231. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL: The Bcr-Abl leukemia oncogene 264. Shenkenberg TD, Waddell CC, Rice L: Erythrocytosis and marked leukocytosis in
activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 92: overlapping myeloproliferative diseases. South Med J 75:868, 1982.
11746, 1995. 265. Haas O, Hinterberger W, Morz R: Pure red cell aplasia as possible early manifestation
232. Miyamura T, Nishimura J, Yufu Y, Nawata H: Interaction of BCR-ABL with the retin- of chronic myeloid leukemia. Am J Hematol 27:20, 1986.
oblastoma protein in Philadelphia chromosome-positive cell lines. Int J Hematol 67: 266. Mijovic A, Rolovic Z, Novak A, et al: Chronic myeloid leukemia associated with pure
115, 1997. red cell aplasia and terminating in promyelocytic transformation. Am J Hematol 31:
233. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG: NF1 deficiency causes Ras- 128, 1989.
mediated granulocyte/macrophage colony stimulating factor hypersensitivity and 267. Inbal A, Akstein E, Barak I, et al: Cyclic leukocytosis and long survival in chronic
chronic myeloid leukaemia. Nat Genet 12:137, 1996. myeloid leukemia. Acta Haematol 69:353, 1983.
234. Amos TA, Lewis JL, Grand FH, et al: Apoptosis in chronic myeloid leukaemia: Nor- 268. Umemura T, Hirata J, Kaneko S, et al: Periodic appearance of erythropoietin-inde-
mal responses by progenitor cells to growth factor deprivation, X-irradiation and glu- pendent erythropoiesis in chronic myelogenous leukemia with cyclic oscillation. Acta
cocorticoids. Br J Haematol 91:387, 1995. Haematol 76:230, 1986.
235. Bedi A, Barber JP, Bedi GC, et al: BCR-ABL-mediated inhibition of apoptosis with 269. Mitus WJ, Kiossoglou KA: Leukocyte alkaline phosphatase in myeloproliferative syn-
delay of G2/M transition after DNA damage: A mechanism of resistance to multiple drome. Ann N Y Acad Sci 155:976, 1968.
anticancer agents. Blood 86:1148, 1995. 270. DePalma L, Delgado P, Werner M: Diagnostic discrimination and cost-effective assay
236. Amarante-Mendes GP, Naekyung KC, Liu L, et al: Bcr-Abl exerts its antiapoptotic strategy for leukocyte alkaline phosphate. Clin Chim Acta 6:83, 1996.
effect against diverse apoptotic stimuli through blockage of mitochondrial release of 271. Pedersen F: Functional and biochemical phenotype in relation to cellular age of differ-
cytochrome C and activation of caspase-3. Blood 92:1700, 1998. entiated neutrophils in chronic myeloid leukemia. Br J Haematol 51:339, 1982.
237. Maguer-Satta V, Burl S, Liu L, et al: BCR-ABL accelerates C2-ceramide-induced apop- 272. Rambaldi A, Terao M, Bettoni S, et al: Differences in the expression of alkaline phos-
tosis. Oncogene 16:237, 1998. phatase in mRNA in chronic myelogenous leukemia and paroxysmal nocturnal
238. Pierson BA, Miller JS: CD56+bright and CD56+dim natural killer cells in patients hemoglobinuria polymorphonuclear leukocytes. Blood 73:1113, 1989.
with chronic myelogenous leukemia progressively decrease in number, respond less to 273. Perillie PE: Studies of the changes in leukocyte alkaline phosphatase following pyro-
stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation gen stimulation in chronic granulocytic leukemia. Blood 29:401, 1967.
on a per cell basis. Blood 88:2279, 1996. 278. Kamada N, Uchino H: Chronologic sequence in appearance of clinical and laboratory
239. Gissinger H, Kurzrock R, Wetzler M, et al: Apoptosis in chronic myelogenous leuke- findings characteristic of chronic myelocytic leukemia. Blood 51:843, 1978.
mia: Studies of stage-specific differences. Leuk Lymphoma 25:121, 1997. 279. Denburg JA, Wilson WE, Goodacre R, Bienenstock J: Chronic myeloid leukemia: Evi-
240. Boultwood J, Peniket A, Watkins F, et al: Telomere length shortening in chronic myel- dence for basophil differentiation and histamine synthesis from cultured peripheral
ogenous leukemia is associated with reduced time to accelerated phase. Blood 96:358, blood cells. Br J Haematol 45:13, 1980.
2000. 280. Goh KO, Anderson FW: Cytogenetic studies in basophilic chronic myelocytic leuke-
241. Terasaki Y, Okamura H, Ohtake S, Nakao S: Accelerated telomere length shortening mia. Arch Pathol Lab Med 103:288, 1979.
in granulocytes: A diagnostic marker for myeloproliferative diseases. Exp Hematol 281. Valent P, Agis H, Sperr W, et al: Diagnostic and prognostic value of new biochemical
30:1399, 2002. and immunohistochemical parameters in chronic myeloid leukemia. Leuk Lymphoma
242. Drummond MW, Lennard A, Brummendorf TH, Holyoake TL: Telomere shortening 49:635, 2008.
correlates with prognostic score at diagnosis and proceeds rapidly during progression 282. Samorapoompichit P, Kiener HP, Schernthaner GH, et al: Detection of tryptase in
of chronic myeloid leukemia. Leuk Lymphoma 45:1775, 2004. cytoplasmic granules of basophils in patients with chronic myeloid leukemia and
243. Campbell LJ, Fidler C, Eagleton H, et al: HTERT, the catalytic component of other myeloid neoplasms. Blood 98:2580, 2001.
telomerase, is downregulated in the haematopoietic stem cells of patients with chronic 283. Weil SC, Hrisinko MA: A hybrid eosinophilic-basophilic granulocyte in chronic gran-
myeloid leukaemia. Leukemia 20:671, 2006. ulocytic leukemia. Am J Clin Pathol 87:66, 1987.
244. Ohyashiki K, Ohyashiki JH, Iwama H, et al: Telomerase activity and cytogenetic 284. Velardi A, Rambotti P, Cernetti C, et al: Monoclonal antibody defined T-cell phe-
changes in chronic myeloid leukemia with disease progression. Leukemia 11:190, 1997. notypes and phytohemagglutinin reactivity of E-rosette forming circulating lympho-
245. Brümmendorf TH, Ersöz I, Hartmann U, et al: Telomere length in peripheral blood cytes from untreated chronic myelocyte leukemia patients. Cancer 53:913, 1984.
granulocytes reflects response to treatment with imatinib in patients with chronic 285. Dowding C, Th’ng KH, Goldman JM, Galton DA: Increased T-lymphocyte numbers
myeloid leukemia. Blood 101:375, 2003. in chronic granulocytic leukemia before treatment. Exp Hematol 12:811, 1984.

Kaushansky_chapter 89_p1437-1490.indd 1477 9/18/15 3:42 PM